Skip to content

Author

M. Matasar

We have 2 of 406 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

It is concluded that access to long-term care plans is highly heterogeneous, with insufficient adaptation to the specific needs of haematological malignancy survivors treated curatively or non-curatively, and it is proposed that clinical trials should include extended follow-up, direct patient reporting, and innovative...

T. Wästerlid, B. Valcárcel, Diana Presno et al. · 2 citations
Open access Sep 2026

Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.

Mosunetuzumab is highly effective against many B-cell lymphomas, but longitudinal immune changes induced by intermittently dosed CD20×CD3 bispecific antibodies remain incompletely characterized. We performed immune profiling of peripheral blood samples from patients receiving fixed-duration (6 months) subcutaneous mosu...

C. Milrod, A. Chorzalska, D. Bonal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.